182 related articles for article (PubMed ID: 36119832)
21. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US
World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267
[TBL] [Abstract][Full Text] [Related]
22. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response.
Besser MJ; Itzhaki O; Ben-Betzalel G; Zippel DB; Zikich D; Kubi A; Brezinger K; Nissani A; Levi M; Zeltzer LA; Ben-Nun A; Asher N; Shimoni A; Nagler A; Markel G; Shapira-Frommer R; Schachter J
Mol Carcinog; 2020 Jul; 59(7):736-744. PubMed ID: 32250515
[TBL] [Abstract][Full Text] [Related]
24. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.
Mullinax JE; Hall M; Prabhakaran S; Weber J; Khushalani N; Eroglu Z; Brohl AS; Markowitz J; Royster E; Richards A; Stark V; Zager JS; Kelley L; Cox C; Sondak VK; Mulé JJ; Pilon-Thomas S; Sarnaik AA
Front Oncol; 2018; 8():44. PubMed ID: 29552542
[TBL] [Abstract][Full Text] [Related]
25. Tumor-Infiltrating T Cells Can Be Expanded Successfully from Primary Uveal Melanoma after Separation from Their Tumor Environment.
Gezgin G; Visser M; Ruano D; Santegoets SJ; de Miranda NFCC; van der Velden PA; Luyten GPM; van der Burg SH; Verdegaal EM; Jager MJ
Ophthalmol Sci; 2022 Jun; 2(2):100132. PubMed ID: 36249685
[TBL] [Abstract][Full Text] [Related]
26. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.
Creelan BC; Wang C; Teer JK; Toloza EM; Yao J; Kim S; Landin AM; Mullinax JE; Saller JJ; Saltos AN; Noyes DR; Montoya LB; Curry W; Pilon-Thomas SA; Chiappori AA; Tanvetyanon T; Kaye FJ; Thompson ZJ; Yoder SJ; Fang B; Koomen JM; Sarnaik AA; Chen DT; Conejo-Garcia JR; Haura EB; Antonia SJ
Nat Med; 2021 Aug; 27(8):1410-1418. PubMed ID: 34385708
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
Mehta GU; Malekzadeh P; Shelton T; White DE; Butman JA; Yang JC; Kammula US; Goff SL; Rosenberg SA; Sherry RM
J Immunother; 2018 Jun; 41(5):241-247. PubMed ID: 29672342
[TBL] [Abstract][Full Text] [Related]
28. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.
Goff SL; Dudley ME; Citrin DE; Somerville RP; Wunderlich JR; Danforth DN; Zlott DA; Yang JC; Sherry RM; Kammula US; Klebanoff CA; Hughes MS; Restifo NP; Langhan MM; Shelton TE; Lu L; Kwong ML; Ilyas S; Klemen ND; Payabyab EC; Morton KE; Toomey MA; Steinberg SM; White DE; Rosenberg SA
J Clin Oncol; 2016 Jul; 34(20):2389-97. PubMed ID: 27217459
[TBL] [Abstract][Full Text] [Related]
29. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
[TBL] [Abstract][Full Text] [Related]
30. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
Huang H; Nie CP; Liu XF; Song B; Yue JH; Xu JX; He J; Li K; Feng YL; Wan T; Zheng M; Zhang YN; Ye WJ; Li JD; Li YF; Li JY; Cao XP; Liu ZM; Zhang XS; Liu Q; Zhang X; Liu JH; Li J
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35727633
[TBL] [Abstract][Full Text] [Related]
32. Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future.
Betof Warner A; Corrie PG; Hamid O
Clin Cancer Res; 2023 May; 29(10):1835-1854. PubMed ID: 36485001
[TBL] [Abstract][Full Text] [Related]
33. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
34. Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy.
Bevins NJ; Okamura R; Montesion M; Adashek JJ; Goodman AM; Kurzrock R
J Immunother Precis Oncol; 2022 Nov; 5(4):90-97. PubMed ID: 36483582
[TBL] [Abstract][Full Text] [Related]
35. Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma.
Borch TH; Andersen R; Ellebaek E; Met Ö; Donia M; Svane IM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32747469
[TBL] [Abstract][Full Text] [Related]
36. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
Dudley ME; Gross CA; Langhan MM; Garcia MR; Sherry RM; Yang JC; Phan GQ; Kammula US; Hughes MS; Citrin DE; Restifo NP; Wunderlich JR; Prieto PA; Hong JJ; Langan RC; Zlott DA; Morton KE; White DE; Laurencot CM; Rosenberg SA
Clin Cancer Res; 2010 Dec; 16(24):6122-31. PubMed ID: 20668005
[TBL] [Abstract][Full Text] [Related]
37. Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.
Bence C; Hofman V; Chamorey E; Long-Mira E; Lassalle S; Albertini AF; Liolios I; Zahaf K; Picard A; Montaudié H; Lacour JP; Passeron T; Andea AA; Ilie M; Hofman P
J Eur Acad Dermatol Venereol; 2020 May; 34(5):984-994. PubMed ID: 31625630
[TBL] [Abstract][Full Text] [Related]
38. [An exploratory clinical study of the efficacy and safety of tumor-infiltrating lymphocytes in the treatment of metastatic osteosarcoma].
Wang CR; Kang M; Xu J; Lyu Y; Jiang YF; Sun MX; Zuo DQ; Shen JK; Ma XJ; Sun W; Hua YQ; Cai Z
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2421-2427. PubMed ID: 36000370
[No Abstract] [Full Text] [Related]
39. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
Dudley ME; Yang JC; Sherry R; Hughes MS; Royal R; Kammula U; Robbins PF; Huang J; Citrin DE; Leitman SF; Wunderlich J; Restifo NP; Thomasian A; Downey SG; Smith FO; Klapper J; Morton K; Laurencot C; White DE; Rosenberg SA
J Clin Oncol; 2008 Nov; 26(32):5233-9. PubMed ID: 18809613
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
Li J; Chen QY; He J; Li ZL; Tang XF; Chen SP; Xie CM; Li YQ; Huang LX; Ye SB; Ke M; Tang LQ; Liu H; Zhang L; Guo SS; Xia JC; Zhang XS; Zheng LM; Guo X; Qian CN; Mai HQ; Zeng YX
Oncoimmunology; 2015 Feb; 4(2):e976507. PubMed ID: 25949875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
